Heart Attack

The Assistance Fund Opens New Program for Myeloproliferative Neoplasms

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Myeloproliferative Neoplasms ORLANDO, FLORIDA / ACCESS Newswire…

19 hours ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL…

1 day ago

Life Line Screening (Updated): What You Need to Know?

New York City,, Jan. 01, 2026 (GLOBE NEWSWIRE) -- in 2026, The greatest way to stay healthy and avoid illnesses…

1 week ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated…

1 week ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect…

1 week ago

How Does Ozempic Work For Weight Loss? Best Weight Loss Supplement Launch By PhenQ

Ozempic for Weight Loss: Does It Work and Is It Safe? Read PhenQ Details – Best Weight Loss Supplement Phenq…

2 weeks ago

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial1Wegovy® pill is indicated to reduce excess…

2 weeks ago

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability…

4 weeks ago

Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease

Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England’s National…

4 weeks ago

New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD

New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to…

4 weeks ago